中国普外基础与临床杂志2024,Vol.31Issue(12) :1430-1433.DOI:10.7507/1007-9424.202410011

原发性肝癌的精准消融治疗

Precise ablation therapy for primary liver cancer

闫煜政 肖嗣傑 马宽生
中国普外基础与临床杂志2024,Vol.31Issue(12) :1430-1433.DOI:10.7507/1007-9424.202410011

原发性肝癌的精准消融治疗

Precise ablation therapy for primary liver cancer

闫煜政 1肖嗣傑 1马宽生1
扫码查看

作者信息

  • 1. 陆军军医大学第一附属医院肝胆外科(重庆 400038)
  • 折叠

摘要

2022年中国原发性肝癌发病人数36.77万人,死亡人数31.65万人.射频消融(radiofrequency ablation,RFA)是肝癌的根治性治疗方式之一,具有疗效确切、微创、价廉等特点,在早期肝癌患者中疗效与手术切除相似.精准外科理念的提出和实践为提高RFA疗效提供了新思路.笔者团队基于万余例RFA治疗经验,开展原发性肝癌精准消融治疗研究,现笔者将结合现有文献及团队经验,论述精准外科理念在RFA治疗中的应用与前景.

Abstract

In 2022,there were 367.7 thousands new cases and 316.5 thousands deaths of primary liver cancer in China.Radiofrequency ablation(RFA)is one of the radical treatments for liver cancer.It has the characteristics of definite curative effect,minimal invasion and low cost.In patients with early liver cancer,the curative effect is similar to surgical resection.The concept and practice of precision surgery provide new ideas for improving the efficacy of RFA.Based on the RFA treatment experience of more than ten thousand cases,the author's team has carried out research on the precise ablation treatment of primary liver cancer.Now,the author will combine the existing literature and our team's experience to discuss the application and prospect of the precise surgery concept in RFA treatment.

关键词

原发性肝癌/射频消融/精准治疗

Key words

primary liver cancer/radiofrequency ablation/precise therapy

引用本文复制引用

出版年

2024
中国普外基础与临床杂志
四川大学华西医院

中国普外基础与临床杂志

CSTPCD
影响因子:0.858
ISSN:1007-9424
段落导航相关论文